{
  "symbol": "BEIGF",
  "company": "BeOne Medicines Ltd.",
  "generated_at": "2026-06-24T07:36:45.637Z",
  "event_count": 3,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-06-18T23:21:29.345Z",
      "stage": "scout",
      "outcome": "unparseable",
      "reason": null,
      "trigger": "[insider_cluster_universe] 3 Form 4 filings in last 14 days · at least one open-market P/S trade verified",
      "source": "idle_hunter"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-18T23:21:29.324Z",
      "summary": "{\"symbol\":\"BEIGF\",\"company\":\"BeOne Medicines AG (ADRs, listed as BEIGF representing 1/13th of ONC)\",\"investigation_summary\":\"BEIGF is the OTC ADR quote for BeOne Medicines Ltd. (Nasdaq: ONC), a $29.6B global oncology company anchored by BRUKINSA (zanubrutinib). The investigation was triggered on an insider cluster signal, but upon detailed Form 4 review, all three June 16, 2026 filings (CEO John O",
      "verdict": "unparseable",
      "tool_calls": 20,
      "walltime_min": 25,
      "debug_path": "dossiers/2026-06-18-BEIGF.scout.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-10T22:53:22.640Z",
      "summary": "Investigation triggered by a cluster of 5 Form 4 filings within 14 days. After reading each filing in full, all five transactions are S-code (sell) executions — specifically mandatory tax-withholding sales pursuant to RSU vesting schedules for John Oyler (CEO), Xiaobin Wu (COO), Wang Lai (R&D Head), Lee Chan Henry (General Counsel), and Ball Titus B. (PAO). No open-market P-code purchases exist in the recent cluster, and zero option markets are available on this OTC-traded ADR (Nasdaq: ONC). The stock is technically weak (below both 20/50 DMAs; bearish MACD cross) from a ~25 high toward $21.94. Despite meaningful bullish catalysts — FDA accelerated approval of BEQALZI (sonrotoclax), Priority Review for TEVIMBRA + ZIIHERA in first-line HER2+ GEA, Q1 2026 earnings beat, multiple analyst price-target raises to $395-$420 — none translate into a structured trade because BEIGF has no listed options. The pipeline halts here.",
      "verdict": "no_anomaly",
      "confidence": 4,
      "tool_calls": 18,
      "walltime_min": 17,
      "debug_path": "dossiers/2026-06-10-BEIGF.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "BEIGF",
    "call": "HOLD",
    "confidence": 1,
    "score": -2,
    "factors": {
      "below_200dma": "-2",
      "below_50dma": "-1",
      "momentum_strong_up": "+2 (41.1%)",
      "rsi_oversold": "+1 (0)",
      "recent_macd_bearish_cross": "-2 (9d ago)",
      "from_high": "0 (-13.2%)"
    },
    "summary": "HOLD (score -2) · 12-1 mom 41.1% · RSI 0 · below_both · -13.2% from high",
    "last_close": 21.95,
    "one_month_ago_close": 22.5,
    "twelve_month_ago_close": 15.95,
    "twelve_one_momentum_pct": 41.09,
    "rsi_14": 0,
    "ma_stack": "below_both",
    "from_period_high_pct": -13.24,
    "period_high": 25.29,
    "price_targets": {
      "bear": 17.71,
      "fair": 22.17,
      "bull": 29.09,
      "bear_return_pct": -19.3,
      "fair_return_pct": 1,
      "bull_return_pct": 32.5,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": null,
        "target_mean": null,
        "target_high": null,
        "analyst_count": null
      }
    },
    "generated_at": "2026-06-24T07:36:45.635Z"
  }
}